GeneDx, a US-based genetic testing laboratory, has introduced a new suite of genetic tests for inherited cancer, including breast and colon cancer.
To be marketed under OncoGeneDx brand, the new suite of genetic tests include a 26-gene panel for breast and ovarian cancer, an 18-gene panel for pancreatic cancer, an 11-gene panel for endometrial cancer, and a comprehensive cancer panel of 35 genes.
The new suite of genetic tests also include test of the BRCA1 and BRCA2 genes combining sequencing and deletion/duplication analysis, and an Ashkenazi Jewish panel for the three common Ashkenazi Jewish founder mutations in BRCA1 and BRCA2.
The test panels, which include deletion/duplication assessment, provide faster results at low cost compared to testing for a single gene by utilising latest data on all the highly penetrant genes associated with inherited cancer.
Commenting on the launch, GeneDx managing director Sherri Bale said: "We are excited to be launching this suite of tests, as we can now bring our extensive experience in genetic testing along with cutting-edge technologies to bear on this very important public health problem that has tremendous impact on patients and their families."
People who previously had normal BRCA1/2 test results with a family history of breast or ovarian cancer can benefit from the OncoGeneDx breast/ovarian next-generation sequencing panel.
Patients can use the information obtained from OncoGeneDx tests for treatment decisions regarding lumpectomy versus mastectomy and use of chemotherapy.
GeneDx priced its OncoGeneDx tests for inherited cancers competitively and also accepts all commercial insurances.
